Milroy 2003.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 424, non‐small cell lung cancer (stage IIIb or IV, advanced); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = if body weight > 45 kg 10000 IU sc TIW, if body weight < 45 kg 5000 IU sc TIW hb‐target = 12.5‐14 g/dL (women), 13.5‐15 g/dL (men) planned ESA duration = during chemotherapy
Outcomes	Primary: QoL; secondary: Hb, tumor response, survival, transfusion
Notes	study number = 67954
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization